Mass Spectrometry Strategies for Clinical Metabolomics and Lipidomics in Psychiatry, Neurology, and Neuro-Oncology

Abstract

Metabolomics research has the potential to provide biomarkers for the detection of disease, for subtyping complex disease populations, for monitoring disease progression and therapy, and for defining new molecular targets for therapeutic intervention. These potentials are far from being realized because of a number of technical, conceptual, financial, and bioinformatics issues. Mass spectrometry provides analytical platforms that address the technical barriers to success in metabolomics research; however, the limited commercial availability of analytical and stable isotope standards has created a bottleneck for the absolute quantitation of a number of metabolites. Conceptual and financial factors contribute to the generation of statistically under-powered clinical studies, whereas bioinformatics issues result in the publication of a large number of unidentified metabolites. The path forward in this field involves targeted metabolomics analyses of large control and patient populations to define both the normal range of a defined metabolite and the potential heterogeneity (eg, bimodal) in complex patient populations. This approach requires that metabolomics research groups, in addition to developing a number of analytical platforms, build sufficient chemistry resources to supply the analytical standards required for absolute metabolite quantitation. Examples of metabolomics evaluations of sulfur amino-acid metabolism in psychiatry, neurology, and neuro-oncology and of lipidomics in neurology will be reviewed.

Epithelial-to-mesenchymal transition involves triacylglycerol accumulation in DU145 prostate cancer cells

“…It includes the comprehensive analysis of lipid species within a biological sample and the analysis of alterations in lipid content and composition after cell perturbation or pathogenesis 10 . These studies have been proved to be useful in the study of the mechanism of many diseases, as well as in the finding of specific disease biomarkers [11][12][13] . Two different …”

Lipidomics

“…Lipidomics is a suitable tool for disease biomarker discovery in systems biology [94,95]. Comprehensive understanding of its applications is critically important for lipidomics.…”

Metabolomics and its integration with systems biology: PSI 2014 conference panel discussion report

“…Abnormal sulfur amino-acid metabolism is observed in the cerebrospinal fluid (CSF) of Amyotrophic Lateral Sclerosis (ALS) patients [23]. Similarly, the brain glycerophospholipid and sphingolipid metabolisms are drastically altered in Alzheimer's disease (AD) in early disease state [27]. In neonatology metabolomics application are very promising, including perinatal transition, perinatal programming, asphyxia and metabolic diseases.…”